New hope for amyloidosis patients: Long-Term safety trial of AT-02 underway
Disease control
Ongoing
This study is testing the long-term safety of an investigational drug called AT-02 in people with systemic amyloidosis, a disease where abnormal proteins build up in organs. About 120 adults who have already been in a previous AT-02 study will receive the drug for an extended per…
Phase: PHASE2 • Sponsor: Attralus, Inc. • Aim: Disease control
Last updated May 17, 2026 09:08 UTC